Impact of Atogepant on Activity Limitation in Participants With Episodic Migraine and Chronic Migraine: Post Hoc Analyses of ADVANCE, ELEVATE, and PROGRESS (P9-12.004)
To evaluate the proportion of participants treated with atogepant (Ato) versus placebo (Pbo) reporting they had no activity limitations on a daily diary measure with scores calculated for Weeks 1, 2, 3, and 4 across three phase 3 Ato trials.
Authors
- Richard B. Lipton (ORCID: https://orcid.org/0000-0003-2652-2897)
- Brett Dabruzzo (ORCID: https://orcid.org/0009-0008-3048-2633)
- Dawn C. Buse (ORCID: https://orcid.org/0000-0002-3784-6144)
- Rashmi B. Halker Singh (ORCID: https://orcid.org/0000-0002-4280-4440)
- Hsiangkuo Yuan (ORCID: https://orcid.org/0000-0002-4536-9974)
- Pranav Gandhi (ORCID: https://orcid.org/0009-0008-8317-7712)
- Kandavadivu Umashankar (ORCID: https://orcid.org/0000-0003-1138-8533)
- Andreas R. Gantenbein (ORCID: https://orcid.org/0000-0001-5686-0200)
- Jonathan Stokes
- Molly Duan
Institutions
- Albert Einstein College of Medicine (US)
- Thomas Jefferson University (US)
- WinnMed (US)
- AbbVie (United States) (US)
- Stiftung für Forschung in Spätantike und Mittelalter HR. Sennhauser (CH)
- AbbVie (Japan)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208534
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00